Camp4 Therapeutics Corporation CAMP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 40.21% | 160.53% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.21% | 160.53% | -- | -- | -- |
| Cost of Revenue | -3.73% | -2.59% | -- | -- | -- |
| Gross Profit | 7.28% | 9.12% | -- | -- | -- |
| SG&A Expenses | 8.56% | 13.86% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.15% | 2.09% | -- | -- | -- |
| Operating Income | 2.41% | 2.40% | -- | -- | -- |
| Income Before Tax | -107.10% | -66.69% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.10% | -66.69% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.10% | -66.69% | -- | -- | -- |
| EBIT | 2.41% | 2.40% | -- | -- | -- |
| EBITDA | 2.75% | 2.59% | -- | -- | -- |
| EPS Basic | 91.62% | 95.65% | -- | -- | -- |
| Normalized Basic EPS | 91.68% | 95.69% | -- | -- | -- |
| EPS Diluted | 91.62% | 95.65% | -- | -- | -- |
| Normalized Diluted EPS | 91.68% | 95.69% | -- | -- | -- |
| Average Basic Shares Outstanding | 238.93% | 314.15% | -- | -- | -- |
| Average Diluted Shares Outstanding | 238.93% | 314.15% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |